What is the intrinsic value of Apellis?
As of 2025-12-26, the Intrinsic Value of Apellis Pharmaceuticals Inc (APLS) is
1.78 USD. This Apellis valuation is based on the model Peter Lynch Fair Value.
With the current market price of 25.16 USD, the upside of Apellis Pharmaceuticals Inc is
-92.93%.
Is Apellis undervalued or overvalued?
Based on its market price of 25.16 USD and our intrinsic valuation, Apellis Pharmaceuticals Inc (APLS) is overvalued by 92.93%.
Apellis Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(555.48) - (82.70) |
(141.44) |
-662.2% |
| DCF (Growth 10y) |
(122.20) - (795.85) |
(206.36) |
-920.2% |
| DCF (EBITDA 5y) |
(48.98) - (58.44) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(87.22) - (113.39) |
(1,234.50) |
-123450.0% |
| Fair Value |
1.78 - 1.78 |
1.78 |
-92.93% |
| P/E |
6.95 - 11.73 |
8.76 |
-65.2% |
| EV/EBITDA |
10.01 - 31.47 |
17.65 |
-29.8% |
| EPV |
(37.65) - (56.38) |
(47.02) |
-286.9% |
| DDM - Stable |
4.43 - 29.95 |
17.19 |
-31.7% |
| DDM - Multi |
(48.23) - (255.21) |
(81.29) |
-423.1% |
Apellis Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
3,183.49 |
| Beta |
1.01 |
| Outstanding shares (mil) |
126.53 |
| Enterprise Value (mil) |
3,159.00 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.35% |
| Cost of Debt |
6.55% |
| WACC |
7.24% |